The inhibitory effect of EGCG on melanoma cell migration through the inhibitory effect on EP2 or EP4 was further verified by treating the cells with an EP2 agonist (butaprost) and an EP4 agonist (cay10580) with and without the treatment of cells with EGCG. This evidence concerns the gene PTGER4 and melanoma.